Apr 20, 2026 07:58AM Arcus Biosciences discontinues lung cancer study due to futility

Mar 23, 2026 07:56AM Arcus Biosciences COO Jennifer Jarrett to resign March 30

Mar 2, 2026 06:26AM Arcus Biosciences (RCUS) PT Raised to $49 at Leerink Partners

Feb 25, 2026 04:09PM Arcus Biosciences (RCUS) Tops Q4 EPS by 21c

Feb 23, 2026 05:00PM Arcus presents kidney cancer drug data showing extended survival

Jan 12, 2026 04:29PM Goldman Sachs Resumes Arcus Biosciences (RCUS) at Buy

Jan 8, 2026 03:11AM Morgan Stanley Downgrades Arcus Biosciences (RCUS) to Equalweight

Jan 7, 2026 04:06PM Arcus Biosciences outlines 2026 development plans for casdatifan

Dec 15, 2025 06:41AM Arcus Biosciences (RCUS) PT Raised to $32 at H.C. Wainwright

Dec 12, 2025 03:41PM Arcus Biosciences (RCUS) PT Lowered to $44 at Citi

Dec 12, 2025 11:51AM Arcus Biosciences (RCUS) PT Raised to $32 at H.C. Wainwright

Dec 12, 2025 11:48AM Arcus Biosciences (RCUS) PT Lowered to $30 at Truist Securities

Dec 12, 2025 11:30AM Increasing unusual call option volume: XLB RCUS NXDR XLI TNYA IRBT PRMB

Oct 29, 2025 06:48AM Arcus Biosciences (RCUS) PT Raised to $28 at H.C. Wainwright

Oct 28, 2025 04:59PM Arcus Biosciences (RCUS) Tops Q3 EPS by 1c

Oct 8, 2025 06:42AM Arcus' (RCUS) presentation marks renewed innovation in RCC: Cantor Fitzgerald

Oct 7, 2025 09:24AM Arcus Biosciences (RCUS) PT Raised to $39 at Truist Securities

Oct 7, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Arcus Biosciences (RCUS)

Oct 7, 2025 05:10AM Arcus Biosciences (RCUS) PT Raised to $16 at BofA Securities

Oct 6, 2025 08:04AM Arcus Biosciences reports positive casdatifan data, expands into inflammation

Aug 18, 2025 06:16AM Arcus Biosciences (RCUS) PT Raised to $45 at Mizuho

Jul 10, 2025 08:30AM FDA grants orphan drug status to Arcus' quemliclustat for pancreatic cancer

Jun 3, 2025 06:55AM H.C. Wainwright Reiterates Buy Rating on Arcus Biosciences (RCUS)

May 6, 2025 04:21PM Arcus Biosciences (RCUS) Misses Q1 EPS by 12c

Apr 4, 2025 05:19AM Arcus Biosciences (RCUS) call put ratio 78 calls to 1 put with a focus on December 10 calls

Feb 26, 2025 06:06AM H.C. Wainwright Upgrades Arcus Biosciences (RCUS) to Buy

Feb 25, 2025 04:36PM Arcus Biosciences (RCUS) Tops Q4 EPS by 20c

Feb 19, 2025 06:56AM Arcus Biosciences (RCUS) PT Lowered to $18 at H.C. Wainwright

Feb 18, 2025 06:57AM Arcus Biosciences (RCUS) Retains Rights to Casdatifan, and Announces Pricing of $150 Million Common Stock Offering

Feb 18, 2025 06:52AM Arcus Biosciences (RCUS) Announces 13.64M Share Offering at $11/sh

Dec 22, 2024 04:00AM Barclays shares outlook for Biotech in 2025, names preferred stocks

Nov 6, 2024 05:11PM Arcus Biosciences (RCUS) Tops Q3 EPS by 2c

Nov 5, 2024 09:02AM Arcus Biosciences (RCUS) Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10

Oct 24, 2024 02:42PM Arcus Biosciences (RCUS) PT Raised to $46 at Citi

Oct 24, 2024 01:48PM BofA Securities Reiterates Neutral Rating on Arcus Biosciences (RCUS)

Oct 21, 2024 06:26AM H.C. Wainwright Starts Arcus Biosciences (RCUS) at Neutral

Oct 3, 2024 07:57AM Truist Securities Reiterates Buy Rating on Arcus Biosciences (RCUS)

Oct 2, 2024 04:08PM Arcus Biosciences (RCUS) Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

Aug 27, 2024 04:08PM Arcus Biosciences (RCUS) Secures Up to $250 Million Term Loan Facility from Hercules Capital

Aug 9, 2024 06:08AM Arcus Biosciences (RCUS) PT Lowered to $23 at BofA Securities

Jul 8, 2024 10:48AM Arcus Biosciences (RCUS) PT Lowered to $25 at Barclays

Jul 5, 2024 06:04AM Cantor Fitzgerald Reiterates Overweight Rating on Arcus Biosciences (RCUS)

Jun 24, 2024 06:10AM Arcus Biosciences (RCUS) PT Lowered to $44 at Truist Securities